Breaking News Instant updates and real-time market news.

LOW

Lowe's

$86.15

-5.19 (-5.68%)

08:12
11/21/18
11/21
08:12
11/21/18
08:12

Lowe's price target lowered to $115 from $125 at KeyBanc

KeyBanc analyst Bradley Thomas lowered his price target for Lowe's to $115 from $125, while reiterating an Overweight rating on the shares. The analyst notes that Q3 EPS was above expectations, on tax rate and margins, though comps came in below expectations. The company continues to on-board new executives under the leadership of new CEO Marvin Ellison, and new initiatives to improve productivity and capital efficiency will ramp in the quarters ahead, he contends. Thomas looks for meaningful self-help opportunities to scale in 2019, which keeps him positive, even with moderated expectations for the industry.

LOW Lowe's
$86.15

-5.19 (-5.68%)

11/20/18
LOOP
11/20/18
NO CHANGE
Target $125
LOOP
Buy
Investors should step into Lowe's despite 'messy' quarter, says Loop Capital
Loop Capital analyst Laura Champine lowered her price target for Lowe's to $125 from $130 following the company's Q3 results, which she says had a lot of moving parts. However, investors should step into the stock as the new leadership at Lowe's is "wasting no time in cleaning up operations and the inventory mix," Champine tells investors in a post-earnings research note titled "Messy Quarter as LOW Jettisons Excess Operations." She reduced her earnings estimates to reflect slightly lower sales and margin assumptions but reiterates a Buy rating on the name.
11/20/18
BARD
11/20/18
NO CHANGE
Target $120
BARD
Outperform
Baird a buyer of Lowe's on post-earnings pullback
Baird analyst Peter Benedict lowered his price target on Lowe's shares to $120 from $130 after the company reported mixed Q3 results, with adjusted EPS topping consensus and comp growth of 1.5% that fell short of the consensus forecast of 2.8%. While it is unrealistic to expect that many of the company's chronic and long-standing issues will be fixed overnight, Benedict said he remains a buyer of what he calls a "self-help" story and keeps an Outperform rating on Lowe's shares.
11/21/18
STFL
11/21/18
DOWNGRADE
Target $92
STFL
Hold
Lowe's downgraded to Hold from Buy at Stifel
Stifel analyst John Baugh downgraded Lowe's (LOW) to Hold from Buy and lowered his price target for the shares to $92 from $125. The company's "poor" Q3 results indicate near term execution risks are higher and the macro backdrop is unlikely to improve in the near term either, Baugh tells investors in a post-earnings research note. With macro concerns and execution worries, the analyst feels "it is prudent to step aside on the name at this time." Home Depot (HD) has "widened the gap on performance and it will take some heavy lifting to reverse course," Baugh contends.
11/21/18
FBCO
11/21/18
NO CHANGE
Target $99
FBCO
Neutral
Lowe's price target lowered to $99 from $111 at Credit Suisse
Credit Suisse analyst Seth Sigman lowered his price target for Lowe's to $99 from $111 and reiterated a Neutral rating on the shares. The analyst believes Q3 results reflected a transitional period, where comps were still under pressure due to the many execution and store level issues, although some progress was made in laying the foundational elements of this turnaround including exiting non-core assets and optimizing its assortment and inventory position. Overall, Sigman thinks it is too early to judge the turnaround, and sees many opportunities for improvement although estimates already embed that, and there is risk the demand trends are less supportive. The roadmap in December will be the next major catalyst, he contends.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$0.00

(0.00%)

05:24
12/10/18
12/10
05:24
12/10/18
05:24
Hot Stocks
Roche CEO Daniel O'Day to step down, Genentech CEO William Anderson to succeed »

Roche (RHHBY) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

EA

Electronic Arts

$82.57

-1.29 (-1.54%)

05:22
12/10/18
12/10
05:22
12/10/18
05:22
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

05:21
12/10/18
12/10
05:21
12/10/18
05:21
Hot Stocks
Gilead appoints Roche CEO Daniel O'Day as CEO, chairman »

Gilead Sciences announced…

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

FIVE

Five Below

$95.53

-6.19 (-6.09%)

05:16
12/10/18
12/10
05:16
12/10/18
05:16
Upgrade
Five Below rating change  »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMXAY

Genmab

$0.00

(0.00%)

05:12
12/10/18
12/10
05:12
12/10/18
05:12
Upgrade
Genmab rating change  »

Genmab upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB

$0.00

(0.00%)

05:10
12/10/18
12/10
05:10
12/10/18
05:10
Upgrade
UCB rating change  »

UCB upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWTUY

Swedish Orphan Biovitrum

$0.00

(0.00%)

05:08
12/10/18
12/10
05:08
12/10/18
05:08
Upgrade
Swedish Orphan Biovitrum rating change  »

Swedish Orphan Biovitrum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

, JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

05:06
12/10/18
12/10
05:06
12/10/18
05:06
Upgrade
MorphoSys, Johnson & Johnson rating change  »

MorphoSys upgraded to Buy…

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

SLG

SL Green Realty

$93.32

-2.41 (-2.52%)

05:02
12/10/18
12/10
05:02
12/10/18
05:02
Upgrade
SL Green Realty rating change  »

SL Green Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$74.07

-1.04 (-1.38%)

04:59
12/10/18
12/10
04:59
12/10/18
04:59
Downgrade
Comerica rating change  »

Comerica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

PII

Polaris Industries

$88.44

-2.37 (-2.61%)

04:58
12/10/18
12/10
04:58
12/10/18
04:58
Downgrade
Polaris Industries rating change  »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MPX

Marine Products

$21.59

-0.21 (-0.96%)

04:56
12/10/18
12/10
04:56
12/10/18
04:56
Downgrade
Marine Products rating change  »

Marine Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$67.58

-4.1 (-5.72%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORT

Corcept Therapeutics

$13.06

0.01 (0.08%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Corcept Therapeutics management to meet with B.Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BRG

Bluerock Residential

$9.55

-0.22 (-2.25%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Bluerock Residential management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

GRUB

GrubHub

$76.80

-4.57 (-5.62%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
GrubHub management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 14

    Dec

HWC

Hancock Whitney

$38.24

0.25 (0.66%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Hancock Whitney management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

KMPR

Kemper

$69.81

-2 (-2.79%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Kemper management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

NBGIF

National Bank of Greece

$0.00

(0.00%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
National Bank of Greece management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

RESI

Front Yard Residential

$9.69

(0.00%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Front Yard Residential management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PETQ

PetIQ

$31.46

0.09 (0.29%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
PetIQ management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

AMAG

Amag Pharmaceuticals

$17.53

-0.58 (-3.20%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Amag Pharmaceuticals management to meet with Leerink »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 23

    Mar

ATO

Atmos Energy

$98.80

0.26 (0.26%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Atmos Energy management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

BC

Brunswick

$49.58

-1.56 (-3.05%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Brunswick management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CMCO

Columbus McKinnon

$31.52

-0.88 (-2.72%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Columbus McKinnon management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.